Literature DB >> 33388415

LSR promotes epithelial ovarian cancer cell survival under energy stress through the LKB1-AMPK pathway.

Yusuke Takahashi1, Satoshi Serada2, Tomoharu Ohkawara3, Minoru Fujimoto3, Kosuke Hiramatsu4, Yutaka Ueda4, Tadashi Kimura4, Hiroshi Takemori5, Tetsuji Naka3.   

Abstract

Lipolysis-stimulated lipoprotein receptor (LSR), also known as a component of tricellular tight junctions, is highly expressing in epithelial ovarian cancer (EOC). However, the biological role of LSR in EOC cells remains unclear. In this study, we evaluated liver kinase B1 (LKB1) mediated AMP-activated protein kinase (AMPK) activity and investigated the effect of LSR on EOC cell survival under energy stress. LSR increased the levels of phospho-AMPKα at Thr172 and phospho-acetyl-CoA carboxylase (ACC) at Ser79 via LKB1-AMPK pathway in glucose deprivation in vitro. The increase of P-AMPKα (Thr172) and P-ACC (Ser79) was also detected in tumor microenvironment in vivo. Meanwhile, LSR promoted LKB1 localization at the cell membrane of EOC cells. By cell survival analysis, LSR attenuated glucose deprivation-induced cell death in EOC cells in vitro. Our results suggest that LSR promotes EOC cell survival and tumor growth through the LKB1-AMPK pathway.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AMPK; Cell survival; Energy stress; Epithelial ovarian cancer; LKB1; LSR

Mesh:

Substances:

Year:  2020        PMID: 33388415     DOI: 10.1016/j.bbrc.2020.12.079

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Brucea javanica Oil Emulsion Promotes Autophagy in Ovarian Cancer Cells Through the miR-8485/LAMTOR3/mTOR/ATG13 Signaling Axis.

Authors:  Yihan Wang; Bocen Chen; Man Xiao; Xiaoli Wang; Yunhua Peng
Journal:  Front Pharmacol       Date:  2022-07-25       Impact factor: 5.988

2.  Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer.

Authors:  Yoshikazu Nagase; Kosuke Hiramatsu; Masashi Funauchi; Mayu Shiomi; Tatsuo Masuda; Mamoru Kakuda; Satoshi Nakagawa; Ai Miyoshi; Shinya Matsuzaki; Eiji Kobayashi; Toshihiro Kimura; Satoshi Serada; Yutaka Ueda; Tetsuji Naka; Tadashi Kimura
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.